Media Center

All news News

  • 14 August 2017

    Innovate UK awards Atlas Genetics £2m SBRI phase II Contract

    Innovate UK awards Atlas Genetics £2m SBRI phase II Contract

    Atlas Genetics Ltd., the ultra-rapid Point-Of-Care (POC) molecular diagnostics company, today announces that it has been awarded a two year Innovate UK phase II contract to expand the Sexually Transmitted Infection (STI) test menu for the io® rapid diagnostic platform and support its adoption into UK sexual health clinics.

  • 10 August 2017

    Syndax Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Clinical and Business Update

    Syndax Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Clinical and Business Update

    Syndax Pharmaceuticals, Inc.  ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, today reported its financial results for the second quarter ended  June 30, 2017 . In addition, the Company provided a clinical and business update. As of  June 30, 2017 , Syndax had  $130.0 million  in cash, cash equivalents and short-term investments.

  • 09 August 2017

    Clearside Biomedical, Inc. Announces Second Quarter 2017 Financial Results and Provides Corporate Update

    Clearside Biomedical, Inc. Announces Second Quarter 2017 Financial Results and Provides Corporate Update

    Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today reported financial results for the quarter and six months ended June 30, 2017 and provided an update on its development programs.

  • 08 August 2017

    Clearside Biomedical, Inc. Announces Changes to its Board of Directors

    Clearside Biomedical, Inc. Announces Changes to its Board of Directors

    Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced that George Lasezkay, Pharm.D., J.D. has been appointed to its board of directors, effective immediately.  Dr. Lasezkay will succeed Derek Yoon, who resigned from the board as of August 8, 2017.

  • 07 August 2017

    Clearside Biomedical Announces Completion of Patient Enrollment in Pivotal Phase 3 PEACHTREE Clinical Trial of CLS-TA for Suprachoroidal Administration in Patients with Macular Edema Associated with Non-Infectious Uveitis

    Clearside Biomedical Announces Completion of Patient Enrollment in Pivotal Phase 3 PEACHTREE Clinical Trial of CLS-TA for Suprachoroidal Administration in Patients with Macular Edema Associated with Non-Infectious Uveitis

    Clearside Biomedical, Inc.  (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced completion of patient enrollment in the pivotal PEACHTREE clinical trial.  This Phase 3 clinical trial is evaluating the safety and efficacy of CLS-TA for suprachoroidal administration (“suprachoroidal CLS-TA”), Clearside’s proprietary suspension formulation of the corticosteroid triamcinolone acetonide, for the treatment of macular edema associated with non-infectious uveitis. Patient follow-up in the PEACHTREE trial is 6 months.  Accordingly, Clearside currently expects to report top-line results from the trial in the first quarter of 2018.

  • 11 July 2017

    Preclinical Results Support Entinostat's Role in Targeting the Tumor Microenvironment to Enhance Immune Checkpoint Therapy

    Preclinical Results Support Entinostat's Role in Targeting the Tumor Microenvironment to Enhance Immune Checkpoint Therapy

    Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, in collaboration with The Wistar Institute and Indiana University Melvin and Bren Simon Cancer Center, today announced the publication of a preclinical report demonstrating that entinostat, Syndax's oral, Class-I histone deacetylase inhibitor, enhances the antitumor effect of PD-1 (programmed death receptor-1) blockade through the inhibition of myeloid derived suppressor cells (MDSCs).

  • 11 July 2017

    Clearside Biomedical Announces First Patient Randomized in Phase 2 Clinical Trial of CLS-TA Used Together with Eylea in Patients with Diabetic Macular Edema

    Clearside Biomedical Announces First Patient Randomized in Phase 2 Clinical Trial of CLS-TA Used Together with Eylea in Patients with Diabetic Macular Edema

    Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced the enrollment of the first patient in a phase 2 clinical trial (“TYBEE”) of CLS-TA for suprachoroidal administration (“suprachoroidal CLS-TA”), Clearside’s proprietary suspension formulation of the corticosteroid triamcinolone acetonide, used together with intravitreally administered EYLEA® (aflibercept) (“intravitreal Eylea”) for the treatment of diabetic macular edema (“DME”).

  • 29 June 2017

    FDA Grants Orphan Drug Designation for Ganaxolone in CDKL5 Disorder

    FDA Grants Orphan Drug Designation for Ganaxolone in CDKL5 Disorder

    Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to ganaxolone for the treatment of CDKL5 Disorder. Ganaxolone is currently being evaluated in children with CDKL5 Disorder in a Phase 2 clinical trial. 

  • 27 June 2017

    Marinus Pharmaceuticals Launches the Ganaxolone Clinical Program in Patients with Postpartum Depression

    Marinus Pharmaceuticals Launches the Ganaxolone Clinical Program in Patients with Postpartum Depression

    Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that it has initiated its Phase 2 double-blind, placebo-controlled clinical trial to evaluate the safety, efficacy and pharmacokinetics (PK) of ganaxolone IV in women diagnosed with severe postpartum depression (Magnolia study). 

  • 08 June 2017

    Clearside Biomedicals TANZANITE Extension Study in Patients with Macular Edema Associated with Retinal Vein Occlusion Presented at the 40th Annual Macula Society Meeting

    Clearside Biomedicals TANZANITE Extension Study in Patients with Macular Edema Associated with Retinal Vein Occlusion Presented at the 40th Annual Macula Society Meeting

    Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, announced that, today Charles C. Wykoff , MD, PhD, presented preliminary results from a non-interventional and retrospective trial (the “Extension Study”) of patients who had participated in the completed Phase 2 trial of CLS-TA for suprachoroidal administration (“suprachoroidal CLS-TA”). 74% of RVO Patients Receiving CLS-TA for Suprachoroidal Administration Together with Intravitreally Administered EYLEA® Did Not Receive Any Additional Treatment Over 9 Months.

All publications Media about us